Table 3.
Patient’s characteristics (N = 101).
| Characteristics | Categories | N (%) |
|---|---|---|
| Age | 77 (±4.3) | |
| Sex | Male/female | 51/42 |
| Histology | Liposarcoma | 26 (27.9%) |
| Leiomyosarcoma | 24 (25.8%) | |
| UPS | 14 (15.0%) | |
| Other | 29 (33.1%) | |
| Primary site | Extremities/trunk | 38 (40.8%) |
| Abdomen | 29 (31.1%) | |
| Chest | 6 (0.6%) | |
| Other | 20 (21.5%) | |
| Metastatic sites | Lung | 24 (25.8%) |
| Other | 35 (37.6%) | |
| Lung and other | 34 (36.6%) | |
| PS ECOG | 0–1 | 76 (75.2%) |
| ≥2 | 25 (24.8%) | |
| CIRS | 0–2 | |
| >2 | ||
| N. of medications | ≤3 | 52 (51.4%) |
| >3 | 49 (48.6%) | |
| 1st line chemotherapy | Anthracycline-based | 44 (47.3%) |
| CM | 11 (11.8%) | |
| Other | 15 (16.1%) | |
| CGA | Fit | 39 (38.6%) |
| Vulnerable | 46 (45.6%) | |
| Frail | 16 (15.8%) | |
| Onco-MPI | Low | 0 (0%) |
| Intermediate | 14 (13.9%) | |
| High | 87 (86.1%) |
Legend: ADL = Activities of daily living; CGA = Comprehensive geriatric assessment; CIRS = Cumulative illness rating scale; ECOG = Eastern cooperative oncology group; PS = Performance status.